Cross-Sector entity
That works out to roughly 0.5 stories per week across a 183-day span. The busiest single day carried 3. Merck & Co. is most often covered alongside Bristol Myers Squibb, which appears in 3 of these 14 stories. Coverage clusters in pharma, which accounts for 6 of those 14, with the remainder spread across 5 other categories.
14 verified stories tracked
Last mentioned: 4d ago
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 22 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
That works out to roughly 0.5 stories per week across a 183-day span. The busiest single day carried 3. Merck & Co. is most often covered alongside Bristol Myers Squibb, which appears in 3 of these 14 stories. Coverage clusters in pharma, which accounts for 6 of those 14, with the remainder spread across 5 other categories. Negative sentiment appears in 43% of the tracked stories. Each carries 2.8 original sources on average. We currently track 14 Cross-Sector stories that mention Merck & Co., published between February 19, 2026 and August 20, 2026.
Computed from the 14 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Merck & Co.. Shared-story counts are live from our verified record — not editorial picks.
Target Deadline
Goal for participating nations to reach the 90-70-90 elimination milestones.
Elimination Target
Deadline for reaching the 90-70-90 vaccination, screening, and treatment goals.
Keytruda Patent Cliff
Merck faces the loss of exclusivity for its top-selling cancer immunotherapy.
FDA approves Merck's Lipfendra
The FDA approves Lipfendra, the first oral PCSK9 inhibitor, under the expedited review program for high-risk statin-treated patients.
Expected Closing
Anticipated completion of the acquisition following regulatory reviews.
Marty Makary resigns as FDA Commissioner
Former FDA chief Dr. Marty Makary, who created the expedited drug review pathway, resigns amid political pressure.
Acquisition Announcement
Merck announces definitive agreement to buy Terns for $6.7 billion.
Federal Injunction
A federal judge issues a temporary block on the administration's vaccine agenda, citing public health risks.
Expected Response
The Trump administration is expected to file its initial legal defense regarding executive agency authority.
Fund Launch
Jacinda Ardern officially unveils the dedicated fund for Pacific cervical cancer elimination.
FY 2025 Earnings
Official reporting of full-year financial results and 2026 clinical guidance.
$5.1M Grant Awarded
Major funding secured to scale screening and vaccination across the region.
Public Announcement
Arizona and other state attorneys general publicly detail the health risks associated with the vaccine rollback.
Lawsuit Filed
A coalition of states files a formal complaint against the Trump administration in federal court.
Proposed Schedule Changes
The administration proposes sweeping changes to the national pediatric immunization schedule.
Policy Shift Initiated
RFK Jr. begins implementing a new agenda for federal vaccine oversight and safety reviews.
Cibotercept Data
Anticipated top-line data from the Phase 2 TROPOS trial in PAH patients.
KER-050 Expansion
Initiation of the global Phase 2/3 trial for elritercept in lower-risk MDS.
Capital Infusion
Keros raised $140 million in a follow-on offering to fund late-stage TGF-beta trials.
Regional Assessment
Health audits reveal critical gaps in HPV vaccine coverage across the Pacific Islands.
A growing movement of oncologists is testing lower or shorter courses of checkpoint inhibitors like Opdivo and Keytruda, challenging the FDA's fixed one-year protocol. For health systems, this raises urgent questions about clinical decision support, patient safety, and value-based oncology as real-world evidence mounts.
Biopharma companies face a growing dose-optimization debate as researchers present evidence that checkpoint inhibitors such as Opdivo and Keytruda can be effective at fractions of FDA-approved doses. Regulatory and commercial models built on fixed dosing face pressure to incorporate dose-ranging data.
Source: edition.cnn.com · freerepublic.com
The FDA approval of Merck's Lipfendra introduces an oral alternative to injectable PCSK9 inhibitors, promising easier patient access and potential cost savings for health systems managing high cholesterol.
Source: mynbc5.com · wjcl.com
Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, securing a high-potential leukemia treatment. The deal is a strategic move to diversify Merck's oncology portfolio as it prepares for the 2028 patent expiration of its top-selling drug, Keytruda.
Merck has reached a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, securing a promising Phase 2 leukemia treatment. The cash deal is a strategic move to diversify Merck's oncology portfolio as it prepares for the 2028 patent expiration of its blockbuster drug Keytruda.
A federal judge has issued a temporary injunction against Robert F. Kennedy Jr.’s proposed changes to national vaccine policy, citing potential risks to public health. The ruling provides a reprieve for pharmaceutical manufacturers and public health agencies while the legal merits of the administration's agenda are debated.
South Carolina health officials have already allocated $1.6 million to contain a significant measles outbreak that shows no signs of immediate resolution. The expenditure highlights the massive economic burden of vaccine-preventable diseases on state public health infrastructures.
Former New Zealand Prime Minister Jacinda Ardern has launched a dedicated health fund to combat the disproportionately high rates of cervical cancer in Pacific Island nations. The initiative focuses on scaling HPV DNA testing and vaccination programs to meet WHO elimination targets by 2030.
A new $5.1 million grant has been awarded to accelerate cervical cancer elimination efforts across the Pacific region, focusing on HPV vaccination and advanced screening. The initiative aligns with the WHO's global strategy to eradicate the disease through the 90-70-90 targets by 2030.
Keros Therapeutics reported robust fourth-quarter and full-year 2025 financial results, highlighting significant clinical progress across its TGF-β superfamily pipeline. The company remains well-capitalized to advance its lead assets, elritercept and cibotercept, through critical Phase 2 and Phase 3 milestones in 2026.
California and 14 other states have filed a federal lawsuit against the Trump administration, challenging recent modifications to the recommended childhood immunization schedule. The coalition argues that these changes lack scientific justification and threaten to undermine decades of public health progress.
A coalition of over a dozen states, led by Arizona, has filed a federal lawsuit against the Trump administration to block the rollback of childhood vaccine recommendations. The plaintiffs argue that the changes to CDC guidelines bypass scientific protocols and present an immediate threat to national public health safety.
A coalition of 15 Democratic-led states has filed a lawsuit against the Trump administration to block changes that reduce the recommended childhood vaccine schedule. The plaintiffs argue that the policy shift ignores scientific consensus and poses a significant risk of infectious disease outbreaks across the country.
A landmark study reveals that the excruciating tropical disease Chikungunya is now capable of local transmission across most of Europe. Driven by the northward migration of the Aedes albopictus mosquito, this shift creates an urgent demand for vaccines and diagnostic infrastructure in previously unaffected regions.
Source: theguardian.com · aol.co.uk
